Basilea Pharmaceutica - Final oncology asset (lisavanbulin) divested
Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the remaining drug...
359 Views
Basilea Pharmaceutica - Cresemba milestone payments continue to roll in
Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in...
363 Views
Basilea Pharmaceutica - Need for innovation against severe infections
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies...
195 Views
Basilea Pharmaceutica - CARB-X grant for preclinical programs
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from...
311 Views
Basilea Pharmaceutica - Zevtera crosses key US regulatory hurdle
Basilea has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe bacterial infections (three...
348 Views